These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26115839)

  • 1. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
    Zhou F; Jiang T; Ma W; Gao G; Chen X; Zhou C
    Lung Cancer; 2015 Aug; 89(2):203-11. PubMed ID: 26115839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Cai H; Lin Y; Li W; Li X
    Clin Lung Cancer; 2013 Jul; 14(4):333-41. PubMed ID: 23276822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
    Liu J; Sheng Z; Zhang Y; Li G
    Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
    Halvorsen TO; Stokke K; Killingberg KT; Raj SX; Sørhaug S; Brustugun OT; Fløtten Ø; Helbekkmo N; Hornslien K; Madebo T; Fluge S; Grønberg BH
    Acta Oncol; 2020 Sep; 59(9):1051-1057. PubMed ID: 32543258
    [No Abstract]   [Full Text] [Related]  

  • 10. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
    Zhao H; Fan Y; Ma S; Song X; Han B; Cheng Y; Huang C; Yang S; Liu X; Liu Y; Lu S; Wang J; Zhang S; Zhou C; Wang M; Zhang L;
    J Thorac Oncol; 2015 Apr; 10(4):655-64. PubMed ID: 25546556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.
    Zhang Q; Dai HH; Dong HY; Sun CT; Yang Z; Han JQ
    Lung Cancer; 2014 Sep; 85(3):339-45. PubMed ID: 25043903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang X; Zang J; Xu J; Bai C; Qin Y; Liu K; Wu C; Wu M; He Q; Zhang S; Wei L; He J
    Chest; 2011 Jul; 140(1):117-126. PubMed ID: 21436247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
    Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
    Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
    Lung Cancer; 2012 Aug; 77(2):331-8. PubMed ID: 22546678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
    Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.
    Mazières J; Brugger W; Cappuzzo F; Middel P; Frosch A; Bara I; Klingelschmitt G; Klughammer B
    Lung Cancer; 2013 Nov; 82(2):231-7. PubMed ID: 23972450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
    Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.